The FDA moved to lock in stability for its top drug and biologics leadership by naming permanent directors for CDER and CBER. Michael Davis will lead CDER and Karim Mikhail will lead CBER, following a period of acting appointments tied to prior leadership turbulence. The change also included a new deputy commissioner role focused on technology and artificial intelligence, reflecting the agency’s intent to formalize oversight structures as AI-enabled products proliferate. For developers, the practical impact is the potential for more consistent decision-making on reviews, labeling, and post-market expectations as leadership continuity returns to key regulatory nodes.